Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interview: KoBioLabs Pioneering The Microbiome Landscape In Korea

Executive Summary

Industry interest in the development of microbiome modulators is noticeably increasing worldwide. In South Korea, KoBioLabs is leading the charge to microbiome drug development, helped by a sizable database and biobank. Its founder and CEO GwangPyo Ko talked to Scrip about its core technology, pipeline progress, and general strategy.

You may also be interested in...



KoBioLabs Sees IPO Building Its Credentials As Global Microbiome Player

The Korean microbiome therapeutics developer KoBioLabs will launch a domestic IPO later this month and hopes to grow into a top three global company in the sector by 2025, helped by licensing deals.

The Hunt For Big Fish: How KDDF Is Helping Create Korean Deals

Korea Drug Development Fund CEO H. Samuel Muk talks to Scrip how the government agency has evolved to support the Korean biopharma industry’s R&D and business development activities, as well as what key new projects are underway.

Next Potential Big ADC Player? Korean Firms Take It Up A Notch

Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC123167

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel